

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3850929
<b>Application Number:</b>	09868123
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	5639
<b>Title of Invention:</b>	Cytokine receptor chain
<b>First Named Inventor/Applicant Name:</b>	Mary Collins
<b>Correspondence Address:</b>	Mintz Levin Cohn Ferris Glovsky and Popeo - One financial Center - Boston MA 02111 US - -
<b>Filer:</b>	Diana Collazo
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	22058-514NATL
<b>Receipt Date:</b>	27-AUG-2008
<b>Filing Date:</b>	02-APR-2002
<b>Time Stamp:</b>	18:27:57
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180

RAM confirmation Number	5360
Deposit Account	502762
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed (5B/08)	W2023_7013US_SB08a_2.PDF	640850	no	7
			4063a463a60071d4d498668b8ba3b0cd1e0465a		

### Warnings:

### Information:

A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.

2	NPL Documents	W2023_7013US_AppealBriefbyUCB.PDF	622694	no	12
			a3c0f0602c12747c7760cc9eefaa250d574dd8c74		

### Warnings:

### Information:

3	NPL Documents	W2023_7013US_AppealBriefbyAstraZenecaAB.PDF	1030967	no	19
			7c649fb751c56a419b8b85decc0bb4f151738f55b		

### Warnings:

### Information:

4	NPL Documents	W2023_7013US_AppealBriefbyGlaxoGroup.PDF	2287504	no	46
			5ee0b8f555bdaa770210a419b13746e5c0683309		

### Warnings:

### Information:

5	NPL Documents	W2023_7013US_OppositionreceivedbyEPoffice.PDF	1005176	no	19
			538fb080bc061675a2ff10b09bb7c2b096e036a58		

### Warnings:

### Information:

6	NPL Documents	W2023_7013US_IntlSearchRptPCTUS9929493.PDF	107765	no	3
			43c7d163f1e2c78c2dd8a7690b440d2ba5c965c		

### Warnings:

Information:					
7	NPL Documents	W2023_7013US_IntlSearchRpt PCTUS0521454.PDF	139190 3009466b40fb13f908b9d6c617ab9314623c57	no	3
Warnings:					
Information:					
8	NPL Documents	W2023_7013US_IntlSearchRpt PCTUS2007025418.PDF	327410 908827259f71c2b884a22ba042309aa38aa7b	no	7
Warnings:					
Information:					
9	NPL Documents	W2023_7013US_IL13blockader educeslung.PDF	797431 635f5a95365d059edc351edcfa0a29c0f21231	no	7
Warnings:					
Information:					
10	NPL Documents	W2023_7013US_PreclinicalPha rmacokinetics.PDF	1823540 d805c0abdc6d1747830554b54693cd0f738e	no	15
Warnings:					
Information:					
11	NPL Documents	W2023_7013US_IL13Signaling ThroughtheIL13x2.PDF	826460 d122cd1056564805170992a093116c3dd5382	no	8
Warnings:					
Information:					
12	NPL Documents	W2023_7013US_EfficacyofIL13 Neutralization.PDF	1005765 d00411676d9272942627126604cc3cd067e2d0c1	no	9
Warnings:					
Information:					
13	NPL Documents	W2023_7013US_KineticAnalysi softheInterleukin13.PDF	695055 E91a091baa30c1b797b75572ae07f7d4dde73c	no	6
Warnings:					
Information:					
14	NPL Documents	W2023_7013US_ExpressionofIL 12andIL13mRNAin.PDF	1112287 2c5352aa98711084e6863285b1ab3d2a79bce809	no	8
Warnings:					
Information:					
15	NPL Documents	W2023_7013US_NasalMastCell sinPerennial.PDF	787326 8ba5c76334dc1280907ba581b03bf2a7a0c3999	no	8
Warnings:					

Information:					
16	NPL Documents	W2023_7013US_GeneticSusce ptibilitytoAsthma.PDF	704230	no	7
			f10483d4d4cc497b007d7ba7eda94c6e2093d6d		
Warnings:					
Information:					
17	NPL Documents	W2023_7013US_CytokinesandIL gERegulation.PDF	2208360	no	28
			52a7591686cb85ac97038bd1c6db199414dc02		
Warnings:					
Information:					
18	NPL Documents	W2023_7013US_IL13InducedAir rway.PDF	891816	no	7
			6077d1ed98aeb8c948776087cc23805db127643		
Warnings:					
Information:					
19	NPL Documents	W2023_7013US_NKTcellmediat ed.PDF	687712	no	6
			cb3b6043e7e480885c8518e2c1b9c20a09c8561		
Warnings:					
Information:					
20	NPL Documents	W2023_7013US_AMurineIL4Re ceptor.PDF	1057784	no	9
			c828f85a8927861e1a4d8393d465e027465306		
Warnings:					
Information:					
21	NPL Documents	W2023_7013US_IL13Mediated Worm.PDF	729288	no	7
			d581311ee39a5ee938e0538e956d4db400c56c395		
Warnings:					
Information:					
22	NPL Documents	W2023_7013US_TheroleofIL13. PDF	619638	no	7
			915e1e75286c5fae338d49f1190193e42ba00a12d8		
Warnings:					
Information:					
23	NPL Documents	W2023_7013US_Interleukin13s KeyRole.PDF	292593	no	2
			fa5a38a278d79752ab3ca401ed4e7d86f5b1b2d02		
Warnings:					
Information:					
24	NPL Documents	W2023_7013US_CriticalRolefor L13inthe.PDF	987391	no	8
			1e1eb408ba25911c20c0a401538ab6c7db4999a12f		
Warnings:					

<b>Information:</b>					
25	NPL Documents	W2023_7013US_Bronchialhyperresponsiveness.PDF	494215 65711540ab20cb2790317edf09ab9afce25295288c	no	5
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	W2023_7013US_PolymorphismsNotFound.PDF	165888 3ba5d57ac7db389a164c74b64598044ac376e602	no	2
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	W2023_7013US_Interleukin13CentralMediator.PDF	609736 8ba7b7ddedf33c23d416d6206c62367194d6cd5901	no	5
<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	W2023_7013US_TheroleofEInasthma.PDF	575093 e508b1c135c844726e3277098822a3467b71deb	no	7
<b>Warnings:</b>					
<b>Information:</b>					
29	NPL Documents	W2023_7013US_Receptorsforinterleukin13and.PDF	732541 24dababk51b13e91adc1d3102bae73d61155c3b71	no	8
<b>Warnings:</b>					
<b>Information:</b>					
30	NPL Documents	W2023_7013US_ThePrimaryBindingSubunitof.PDF	981308 65044471c5e42eeec202c583c1db3daa0bba87	no	10
<b>Warnings:</b>					
<b>Information:</b>					
31	NPL Documents	W2023_7013US_RequirementforIL13IndependentlyofIL4.PDF	479545 01336778baad7334942614162851a78940714	no	3
<b>Warnings:</b>					
<b>Information:</b>					
32	NPL Documents	W2023_7013US_AppealBriefbyGenentech.PDF	740653 423dc5da588cc0440ba96f813d83c95017fa23	no	13
<b>Warnings:</b>					
<b>Information:</b>					
33	NPL Documents	W2023_7013US_AppealBriefbySchlich.PDF	395670 934c36d8b84854588537139711aa82b4046c68	no	12
<b>Warnings:</b>					

<b>Information:</b>					
34	Fee Worksheet (PTO-06)	fee-info.pdf	30215 <small>10812808d33e880e1a3eac8b2b95d113a567778</small>	no	2
<b>Warnings:</b>					
<b>Information:</b>					
Total Files Size (in bytes):			26593096		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>          If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>          If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>          If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					